0000000000015040

AUTHOR

Javier Muñiz

0000-0002-3087-2067

showing 5 related works from this author

Complicaciones infecciosas relacionadas con la asistencia circulatoria mecánica de corta duración en candidatos a trasplante cardiaco urgente

2022

Introducción y objetivos El uso de dispositivos de asistencia circulatoria mecánica de corta duración como puente a trasplante es frecuente en España. Se desconocen la epidemiología y la repercusión de las complicaciones infecciosas en estos pacientes. Métodos Descripción sistemática de la epidemiología y análisis de la repercusión pronóstica de las complicaciones infecciosas en un registro multicéntrico retrospectivo de pacientes tratados con dispositivos de asistencia circulatoria mecánica de corta duración como puente a trasplante cardiaco urgente entre 2010 y 2015 en 16 hospitales españoles. Resultados Se estudió a 249 pacientes; 87 (34,9%) de ellos tuvieron un total de 102 infecciones.…

Trasplante de órganos03 medical and health sciences0302 clinical medicineInfeccionesbusiness.industryEnfermedad cardiovascularInsuficiencia cardíacaMedicine030204 cardiovascular system & hematologyAparato respiratorioCardiology and Cardiovascular MedicinebusinessHumanities
researchProduct

Infectious complications associated with short-term mechanical circulatory support in urgent heart transplant candidates

2021

[Abstract] Introduction and objectives. Short-term mechanical circulatory support is frequently used as a bridge to heart transplant in Spain. The epidemiology and prognostic impact of infectious complications in these patients are unknown. Methods. Systematic description of the epidemiology of infectious complications and analysis of their prognostic impact in a multicenter, retrospective registry of patients treated with short-term mechanical devices as a bridge to urgent heart transplant from 2010 to 2015 in 16 Spanish hospitals. Results. We studied 249 patients, of which 87 (34.9%) had a total of 102 infections. The most frequent site was the respiratory tract (n = 47; 46.1%). Microbiol…

medicine.medical_specialtyTrasplante cardiacomedicine.medical_treatmentEnfermedad cardiovascular030204 cardiovascular system & hematologyAsistencia circulatoria mecánica Asistencia ventricular Critical care Cuidados críticos ECMO Heart transplant Infección Infection Mechanical circulatory support Trasplante cardiaco Ventricular assist deviceWaiting period03 medical and health sciences0302 clinical medicineMechanical circulatory supportAsistencia circulatoria mecánicaInternal medicineEpidemiologymedicineHumansInfecciónTrasplante de corazónCuidados críticosRetrospective StudiesHeart Failurebusiness.industryGeneral MedicineAparato respiratorioTrasplante de órganosCritical caremedicine.anatomical_structureTreatment OutcomeSpainVentricular assist deviceCirculatory systemAsistencia ventricularVentricular assist deviceHeart TransplantationHeart transplantHeart-Assist DevicesECMObusinessInfectionMechanical devicesRespiratory tract
researchProduct

Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.

2015

Introduction: Atrial fibrillation (AF) is associated with an increased risk of thromboembolic events. Many patients with AF receive chronic anticoagulation, either with vitamin K antagonists (VKAs) or with non-VKA oral anticoagulants (NOACs). We sought to analyze variables associated with prescription of NOAC. Methods: Patients with AF under anticoagulation treatment were prospectively recruited in this observational registry. The sample comprised 1290 patients under chronic anticoagulation for AF, 994 received VKA (77.1%) and 296 NOAC (22.9%). Univariate and multivariate analyses were performed to identify variables associated with use of NOAC. Results: Mean age was 73.8 ± 9.4 years, and 4…

MaleVitamin KClinical Decision-MakingMEDLINEAdministration OralHemorrhage030204 cardiovascular system & hematologyVitamin kanticoagulant treatment03 medical and health sciences0302 clinical medicineClinical decision makingFibrinolytic AgentsAtrial FibrillationmedicineHumansPharmacology (medical)030212 general & internal medicineAgedPharmacologyAged 80 and overbusiness.industrynonvitamin K antagonist oral anticoagulantsAnticoagulantsAtrial fibrillationMiddle Agedmedicine.diseasevitamin K antagonistsIncreased riskAnticoagulant therapyAnesthesiaOral anticoagulantFemaleCardiology and Cardiovascular Medicinebusiness
researchProduct

Quality of Anticoagulation With Vitamin K Antagonists

2015

Background Vitamin K antagonists (VKA) have a narrow therapeutic range, and literature analysis reveals poor quality of anticoagulation control. We sought to assess the prevalence of poor anticoagulant control in patients under VKA treatment in the prevention of stroke for atrial fibrillation (AF). Hypothesis Control of anticoagulation with VKA is inadequate in a high percentage of patients with AF. Methods Patients with AF under VKA treatment were prospectively recruited in this observational registry. The sample comprised 948 patients. The estimated time spent in the therapeutic range (TTR) was calculated, and variables related with a TTR >65% were analyzed. Results Mean age was 73.8 ± 9.…

medicine.medical_specialtybusiness.industryAtrial fibrillationGeneral MedicineOdds ratiomedicine.diseaseLower riskComorbidityConfidence intervalSurgeryInternal medicinemedicineLiver functionCardiology and Cardiovascular MedicinebusinessProspective cohort studyStrokeClinical Cardiology
researchProduct

Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: a multicountry patient-leve…

2019

Background The precise age distribution and calculated stroke risk of screen-detected atrial fibrillation (AF) is not known. Therefore, it is not possible to determine the number needed to screen (NNS) to identify one treatable new AF case (NNS-Rx) (i.e., Class-1 oral anticoagulation [OAC] treatment recommendation) in each age stratum. If the NNS-Rx is known for each age stratum, precise cost-effectiveness and sensitivity simulations can be performed based on the age distribution of the population/region to be screened. Such calculations are required by national authorities and organisations responsible for health system budgets to determine the best age cutoffs for screening programs and d…

MaleHealth ScreeningEconomicsSocial Sciences030204 cardiovascular system & hematologyVascular MedicineScreening programmeElectrocardiography0302 clinical medicineRisk FactorsHealth careAtrial FibrillationMedicine and Health SciencesMass ScreeningPublic and Occupational Health030212 general & internal medicinemedia_commonAged 80 and overRAge FactorsGeneral MedicineMiddle AgedUniversity hospitalPrognosis3. Good healthStrokeBioassays and Physiological AnalysisNeurologyHealthMedicineFemaleTraining programArrhythmiaResearch ArticleAdultCerebrovascular DiseasesCost-Effectiveness AnalysisCardiologyLibrary scienceResearch and Analysis MethodsRisk AssessmentStroke risk03 medical and health sciencesYoung AdultAge DistributionSex FactorsPopulation MetricsPredictive Value of TestsPolitical sciencemedia_common.cataloged_instanceHumansEarly careerEuropean unionIschemic StrokeAgedHealth Care PolicyPopulation Biologybusiness.industryElectrophysiological TechniquesBiology and Life SciencesNumber needed to screenEconomic AnalysisHealth CareAge GroupsPeople and PlaceseHealthPopulation GroupingsCardiac ElectrophysiologybusinessScreening Guidelines
researchProduct